EIF2AK3 and lung cancer: Additionally, GSK2606414 demonstrates potential in regulating the inflammatory microenvironment of lung cancer by inhibiting PERK, which concurrently attenuates both NF-κB-mediated inflammatory responses and apoptosis (99).